Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. May 14, 2026; 32(18): 118390
Published online May 14, 2026. doi: 10.3748/wjg.v32.i18.118390
Published online May 14, 2026. doi: 10.3748/wjg.v32.i18.118390
Relationship between statin use and inflammatory bowel disease: Exploring possible implications
Antonietta G Gravina, Raffaele Pellegrino, Michele Izzo, Ilaria De Costanzo, Giuseppe Imperio, Assunta Tambaro, Alessia Lamart, Fabio Landa, Alessandro Federico, Division of Hepatogastroenterology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy
Co-first authors: Antonietta G Gravina and Raffaele Pellegrino.
Author contributions: Gravina AG and Pellegrino R conceptualized and designed the framework and methodology of the review; they contributed equally to this manuscript and share first authorship; Gravina AG, Pellegrino R, Izzo M, De Costanzo I, Imperio G, Tambaro A, Lamart A, Landa F, and Federico A reviewed the literature and wrote the initial manuscript, conceptualized the structure of the text and critically revised the manuscript for important intellectual content; all authors have read and approved the final manuscript.
Conflict-of-interest statement: Gravina AG has conducted training activities (e.g., educational continuing medical education preceptorship) for Pfizer, Galapagos Biopharma, and AbbVie. Pellegrino R has received sponsorship for participation in national and/or international conferences from Pfizer Inc., Eli Lilly, Alfasigma, AbbVie, and Takeda. The other authors have no direct or indirect conflicts of interest concerning this work to disclose.
Corresponding author: Raffaele Pellegrino, MD, Division of Hepatogastroenterology, Depart
Received: December 31, 2025
Revised: February 12, 2026
Accepted: February 25, 2026
Published online: May 14, 2026
Processing time: 126 Days and 18.9 Hours
Revised: February 12, 2026
Accepted: February 25, 2026
Published online: May 14, 2026
Processing time: 126 Days and 18.9 Hours
Core Tip
Core Tip: Beyond their lipid-lowering action, statins exert anti-inflammatory and immunomodulatory effects that may influence the onset and course of inflammatory bowel diseases, reducing inflammatory activity and the risk of complications, and positioning themselves as potential complementary therapies.